Abpro Holdings (ABPO) Cash from Financing Activities (2022 - 2026)
Abpro Holdings' (ABPO) quarterly Cash from Financing Activities came in at $7.4 million in Q1 2026, up 8922.62% YoY from $82138.0 in Q1 2025, and up 1964.35% on a QoQ basis from $359000.0 in Q4 2025.
Abpro Holdings (ABPO) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 5 years of Cash from Financing Activities data on file, last reported at $7.4 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 8922.62% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.6 million (up 20.99% YoY) and the FY2025 annual result came in at $3.1 million, down 72.49% from the prior year.
- Cash from Financing Activities advanced to $7.4 million in Q1 2026, from $359000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $307.3 million in Q1 2022 to a low of -$276.5 million in Q2 2023.
- A 5-year average of $25.4 million and a median of $1.2 million in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities tumbled 103.58% — and 2026, when it jumped 8922.62%.
- Tracing ABPO's Cash from Financing Activities over 5 years: stood at -$12000.0 in 2022, then surged by 2311687.17% to $277.4 million in 2023, then tumbled by 97.6% to $6.7 million in 2024, then sank by 94.61% to $359000.0 in 2025, then surged by 1964.35% to $7.4 million in 2026.
- The last three Cash from Financing Activities figures came in at $7.4 million (Q1 2026), $359000.0 (Q4 2025), and $569000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | -123,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.41 Mn |
| Mar 31, 2026 | 7.41 Mn |
| Dec 31, 2025 | 359,000.00 |
| Dec 31, 2025 | 359,000.00 |
| Sep 30, 2025 | 569,000.00 |
| Sep 30, 2025 | 569,000.00 |
| Jun 30, 2025 | 2.23 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Mar 31, 2025 | -84,000.00 |
| Mar 31, 2025 | -84,000.00 |
| Dec 31, 2024 | 6.67 Mn |
| Dec 31, 2024 | 6.67 Mn |
| Sep 30, 2024 | 936,000.00 |
| Sep 30, 2024 | 936,000.00 |
| Jun 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 2.35 Mn |
| Mar 31, 2024 | 2.35 Mn |
| Dec 31, 2023 | 277.39 Mn |
| Dec 31, 2023 | 277.39 Mn |